Hoth Therapeutics (HOTH) Competitors $0.80 +0.00 (+0.56%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$0.81 +0.00 (+0.44%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. RLYB, GBIO, CLNN, CGTX, TENX, CALC, DARE, DRRX, PULM, and GDTCShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Rallybio (RLYB), Generation Bio (GBIO), Clene (CLNN), Cognition Therapeutics (CGTX), Tenax Therapeutics (TENX), CalciMedica (CALC), Daré Bioscience (DARE), DURECT (DRRX), Pulmatrix (PULM), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Rallybio Generation Bio Clene Cognition Therapeutics Tenax Therapeutics CalciMedica Daré Bioscience DURECT Pulmatrix CytoMed Therapeutics Rallybio (NASDAQ:RLYB) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Does the media favor RLYB or HOTH? In the previous week, Rallybio had 12 more articles in the media than Hoth Therapeutics. MarketBeat recorded 13 mentions for Rallybio and 1 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 0.93 beat Rallybio's score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rallybio Neutral Hoth Therapeutics Positive Which has more risk and volatility, RLYB or HOTH? Rallybio has a beta of -1.35, meaning that its stock price is 235% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Do insiders & institutionals believe in RLYB or HOTH? 90.3% of Rallybio shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 10.6% of Hoth Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend RLYB or HOTH? Rallybio currently has a consensus price target of $9.33, suggesting a potential upside of 3,624.39%. Hoth Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 397.20%. Given Rallybio's higher probable upside, equities analysts plainly believe Rallybio is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation and earnings, RLYB or HOTH? Hoth Therapeutics has lower revenue, but higher earnings than Rallybio. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$636K16.40-$74.56M-$1.35-0.19Hoth TherapeuticsN/AN/A-$7.84M-$1.33-0.60 Is RLYB or HOTH more profitable? Rallybio's return on equity of -77.39% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -77.39% -69.33% Hoth Therapeutics N/A -89.68%-82.61% Does the MarketBeat Community favor RLYB or HOTH? Hoth Therapeutics received 33 more outperform votes than Rallybio when rated by MarketBeat users. However, 75.86% of users gave Rallybio an outperform vote while only 66.96% of users gave Hoth Therapeutics an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes4475.86% Underperform Votes1424.14% Hoth TherapeuticsOutperform Votes7766.96% Underperform Votes3833.04% SummaryHoth Therapeutics beats Rallybio on 9 of the 17 factors compared between the two stocks. Remove Ads Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.60M$6.11B$5.19B$7.41BDividend YieldN/A3.03%5.36%4.29%P/E Ratio-0.616.5021.2517.55Price / SalesN/A203.67359.0289.69Price / CashN/A65.6738.1534.64Price / Book0.405.456.143.81Net Income-$7.84M$141.10M$3.19B$247.05M7 Day Performance-4.21%-3.73%-1.91%-0.12%1 Month Performance-28.81%-17.83%-4.29%-9.21%1 Year Performance-36.15%-22.30%1.96%-6.81% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics2.5153 of 5 stars$0.80+0.6%$4.00+397.2%-36.2%$10.60MN/A-0.614RLYBRallybio1.9341 of 5 stars$0.65+2.2%$9.75+1,389.7%-84.6%$27.24M$636,000.00-0.4140Analyst DowngradeGap DownGBIOGeneration Bio4.1749 of 5 stars$0.41-5.3%$7.33+1,710.7%-90.6%$27.14M$19.89M-0.18150Analyst ForecastPositive NewsGap UpCLNNClene2.8397 of 5 stars$3.08-4.3%$55.25+1,693.8%-61.7%$26.45M$342,000.00-0.58100Analyst ForecastGap UpCGTXCognition Therapeutics2.8587 of 5 stars$0.42+1.2%$7.13+1,593.2%-83.9%$26.08MN/A-0.4320TENXTenax Therapeutics1.7798 of 5 stars$6.55+0.9%$18.00+174.8%+40.6%$25.97MN/A-1.239CALCCalciMedica2.2269 of 5 stars$1.91-4.0%$18.00+842.4%-66.4%$25.75MN/A-1.7730DAREDaré Bioscience1.3054 of 5 stars$2.89+0.3%$24.00+730.4%-49.7%$25.14M$1.88M-4.8930DRRXDURECT0.5328 of 5 stars$0.80+0.3%$5.00+523.4%-15.1%$24.90M$8.59M-1.3180Gap UpPULMPulmatrix0.2333 of 5 stars$6.66-7.4%N/A+188.9%$24.31M$7.81M-2.5220Gap DownGDTCCytoMed Therapeutics2.3214 of 5 stars$2.20-2.2%$5.00+127.3%+21.4%$24.07MN/A0.00N/APositive News Remove Ads Related Companies and Tools Related Companies Rallybio Alternatives Generation Bio Alternatives Clene Alternatives Cognition Therapeutics Alternatives Tenax Therapeutics Alternatives CalciMedica Alternatives Daré Bioscience Alternatives DURECT Alternatives Pulmatrix Alternatives CytoMed Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 4/11/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
